financetom
Business
financetom
/
Business
/
US senator says he is concerned energy secretary acting in nuclear firm's interest
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
US senator says he is concerned energy secretary acting in nuclear firm's interest
Sep 23, 2025 10:08 AM

WASHINGTON, Sept 23 (Reuters) - U.S. Senator Edward

Markey sent a letter to President Donald Trump on Tuesday saying

he is concerned U.S. Energy Secretary Chris Wright is working in

the interest of nuclear power company Oklo ( OKLO ), of which he

used to be a board member.

Markey, a Democrat, noted that the administration is moving

ahead with plans to allow Oklo ( OKLO ) to build a nuclear waste

reprocessing plant and transfer government-held plutonium from

nuclear weapons to use as fuel in planned reactor projects.

"Oklo ( OKLO ) stands to benefit financially and Secretary Wright is

acting in his former company's interest," Markey said.

The White House referred a request for comment to the

energy department, which did not respond immediately. Oklo ( OKLO ) said

it had no comment.

Oklo ( OKLO ) said this month it plans to build and operate a plant

in Tennessee to reprocess nuclear waste as the first phase of a

nuclear fuel center costing up to $1.68 billion.

Reuters reported

in August

the government plans to make available 20 metric tons of

plutonium to nuclear companies. Oklo ( OKLO ) has not said it wants to

use the plutonium and the department has not announced plans on

the material.

But an energy department source said Oklo ( OKLO ) has been in touch with

the agency about using the radioactive metal and that top energy

officials were having conversations with the company about it.

Markey asked Trump questions about Wright's connection to

decision making and the Republican secretary's financial

interest in Oklo ( OKLO ).

Trump in May ordered the government to halt much of its existing

program to dispose of plutonium, and instead provide it as a

fuel for reactors.

The idea of using surplus plutonium as fuel and extracting

it from nuclear waste has concerned nuclear safety experts who

say it could increase risks of proliferation and make it hard

for the U.S. to tell other countries not to pursue similar

technologies.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
What's Going On With Rivian (RIVN) Stock?
What's Going On With Rivian (RIVN) Stock?
Sep 20, 2024
Rivian Automotive Inc ( RIVN ) shares are trading lower by 7.5% to $12.17 during Friday’s session. The stock is trading lower as major indexes pull back following recent strength. What Happened This Week: The Federal Reserve’s unexpected decision Wednesday to cut interest rates by 50 basis points at its September Federal Open Market Committee (FOMC) meeting saw markets Rivian stock and broader markets...
BRIEF-Acumen Health Holdings To Acquire The Avenova Brand From Novabay Pharmaceuticals
BRIEF-Acumen Health Holdings To Acquire The Avenova Brand From Novabay Pharmaceuticals
Sep 20, 2024
Sept 20 (Reuters) - NovaBay Pharmaceuticals Inc ( NBY ): * ACUMEN HEALTH HOLDINGS (ACUMEN) TO ACQUIRE THE AVENOVA BRAND FROM NOVABAY PHARMACEUTICALS Source text for Eikon: Further company coverage: ...
Fortress Biotech Prices Registered Direct Offering, Private Placements; Shares Fall
Fortress Biotech Prices Registered Direct Offering, Private Placements; Shares Fall
Sep 20, 2024
12:13 PM EDT, 09/20/2024 (MT Newswires) -- Fortress Biotech ( FBIO ) said Friday it has entered into agreements to sell about 3.9 million shares, or pre-funded warrants in lieu thereof, at $1.65 per share to healthcare focused institutional investors. The firm said it will issue warrants to the investors to buy up to about 3.9 million shares, with an...
AbbVie Says EMA Committee Recommends Marketing Approval of Ovarian Cancer Therapy
AbbVie Says EMA Committee Recommends Marketing Approval of Ovarian Cancer Therapy
Sep 20, 2024
08:29 AM EDT, 09/20/2024 (MT Newswires) -- AbbVie ( ABBV ) said on Friday that the European Medicines Agency's advisory committee has recommended a marketing authorization for the company's ovarian cancer therapy, mirvetuximab soravtansine. The therapy is being developed as a treatment for adult patients with platinum-resistant and epithelial ovarian, fallopian tube or primary peritoneal cancer who have been treated...
Copyright 2023-2026 - www.financetom.com All Rights Reserved